Roche’s Trontinemab (Gantenerumab fused to a monovalent anti-human TfR1-binding Fab fragment) has shown to be safe in healthy individuals and has recently entered Phase II testing in AD patients [81,82]. This evidence concerns the gene TFRC and Alzheimer disease.